Admin touts TrumpRX success: it’s a quick fix, not real progress!  

A new analysis from The New York Times, on with German outlets NDR and WDR, took a person look astatine the administration’s caller cause pricing platform, TrumpRx. What they recovered is that portion immoderate prices person travel down, Americans are inactive paying importantly much than patients successful different affluent countries,